The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?

Ana Lorenzo-Vizcaya, David A Isenberg

Expert opinion on biological therapy 2021 May

filter terms:

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by multiple pathologies in which sustained inflammatory activity leads to progressive tissue destruction and organ damage. One of the main proinflammatory cytokines playing a key role in autoimmune diseases such as rheumatoid arthritis (RA) or SLE, is tumor necrosis factor (TNF) alpha. The introduction of TNF-alpha inhibitors revolutionized the treatment of RA and other conditions including psoriatic arthritis and ankylosing spodylitis. We review here the efficacy and safety of TNF-alpha blockers in SLE focussing on why it has not been more widely used since TNF-alpha was reported to be increased in SLE patients and to correlate with disease activity. We summarize the reported SLE cases that have received TNF-alpha blockers and the main results to date. We reflect on whether there is a case to reconsider the use of TNF-alpha blockade in SLE.

Citation

Ana Lorenzo-Vizcaya, David A Isenberg. The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now? Expert opinion on biological therapy. 2021 May;21(5):639-647